Keep an eye on this tech stock - after years of loses, rights issues, etc things look to be moving in the right direction. Tipped by Redmayne last year it could be a winner.

Its already risen substantially....Good Investment Strategy is to buy stocks at the bottom for the biggest gains when no one else wants to buy them. Should have told me about these when these were right at the bottom not when they have already risen....

Look back at the bigger picture (to 94) its only just started to recover.
Lots more upside.

AT LAST UPSIDE!!!
FUNDING EXERCISE OUT OF THE WAY - STOCK OVERHANG GONE - ONLY WAY IS UP!!

Still moving in the right direction - one Sue Helen missed!!

come on chaps get on board new in the offing - very good news!!

Keeps on rising enen on bad days - new products about to be tested and approve I think!!

transco.
I've been long on this stock since they were 16p.at the rights issue.
They've risen the best part of 20% recently. You are the only poster on this site.Please prove to me that you are not ramping by telling me what news is coming soon.

Look at the news - presentations to the city planned for Dec.
The pipeline is stuffed with new developments.

transco
Yes, I've seen the news re results and presentation 7th Dec.
But a load of sells on that news,perhaps the herd thinks we are in for another rights issue.The price is down a bit today.A massive buy went thro last thing.Is it realy a buy or are mms adjusting?

Now I've checked out the time of the deal, I'm guessing that the big buy was the Friday auction to allow the mms to balance their books. Either way the fact that the auction price was close to the high of the week should mean an extra penny or two next week.

Keep the faith!
After so many false dawns I think its protherics time.
No chance of a rights issue IMHO.

Generating Pharmaceutical Sales Before Marketing Authorization
When a patient has a serious illness and there is no approved drug available, the physician may want to try one which has not been authorized for marketing by national health authorities but has shown promise in clinical trials.This presents drug-makers with an opportunity to generate revenues while development is still in-progress.

Amsterdam, The Netherlands (PRWEB) October 26, 2004 -- When a patient has a serious illness and there is no approved drug available, the physician may want to try one which has not been authorized for marketing by national health authorities but has shown promise in clinical trials. European Named Patient Programs, like US compassionate use programs, offer physicians access to pharmaceuticals which have not yet been licensed. However, there is one important difference: in Europe an unlicensed drug can be reimbursed. This presents drug-makers with an opportunity to generate revenues while development is still in-progress.

Significant Revenues Are Possible
The additional revenues can be considerable. For example, Pharmion, a US based company focusing on Oncology and Hematology reported dramatic increases in its Thalidomide sales from $1.9 million in 2Q 03 to $15.3 million in 2Q 04, primarily due to named patient sales in Europe for Multiple Myeloma. Thalidomide sales accounted for approximately 75% of Pharmions total revenues for the first half of 2004, according to company sources, and were generated while the product awaits marketing approval for this indication. Before receiving European Marketing Approval, Shires Argylin for essential thrombocythaemia generated about 5% of its total sales from its European named patient program.

Though thalidomide and Agrylin were licensed in the USA for some indications, pharmaceutical companies do set-up named patient programs and receive full reimbursement for drugs that are not licensed for any indication in any market. Examples include: Insmeds SomatoKine authorized for named patient use for Primary Lateral Sclerosis, Growth Hormone Insensitivity Syndrome (GHIS) and Severe Insulin Resistance and Protherics ViperaTAb authorized for named patient use for adder snake bites.

Other Benefits of Named Patient Programs
A named patient program can speed uptake after official launch. Physicians, who have had experience before launch, via clinical trials or named patient programs, often become early adopters and references for other physicians once the drug is freely circulating.

Named patient programs, like US compassionate use programs, can increase good-will toward the company because they simplify the process of gaining access for patients in critical need. Smaller companies often can not afford the administrative time and costs of shipping drugs around the world before launch. This can lead to frustration and resentment towards a company that many physicians will remember long after a drug is officially on the market. Creating a formal channel eliminates the unfortunate need of denying requests and risking ill-will later.

A named patient program should be considered an important part of a pre-launch program. It increases awareness to a pharmaceuticals existence, creates excitement, generates good-will and speeds penetration of the product after launch.

Frequent Communication is Necessary
If one of the objectives is to generate revenues, setting up a named patient program is just the beginning. In order to achieve success, physicians need to be aware of the product and what they need to do to get it. Typical methods of informing physicians, such as sales rep visits and ads, may not be appropriate because a license is necessary to market a drug. While physicians are used to simply writing a prescription and being done with it, named patient programs require paper-work that some find tedious. Therefore the company needs to create an appropriate communication plan and work closely with the targeted medical community to keep them informed and simplify the process.

Issues to Consider
You have decided to make a named patient program part of your pre-marketing plan, what now?

Administration: Do you go it alone or work with a company that is experienced at administering named patient programs?

There are several experienced organizations that can assist your company by gaining approval, setting-up the program, doing administration and taking care of physical distribution. If your organization is well resourced and has a pipe-line of products that will require named patient programs, it might be worthwhile acquiring the expertise internally. However, if you have few appropriate products or a stream-lined organization, it is probably best to consider outsourcing.

Communication: Youve set up the program, how do you optimize it?

If you do not have an experienced European marketing group, an organization that is familiar in sales and marketing of pharmaceuticals in Europe can help you to maximize participation in the named patient program. A communication plan, if properly developed and implemented can increase product awareness, but communication concerning an unlicensed product must be done appropriately. This plan should ensure that your entire target group:

Is fully aware of the product AND the program
Knows what needs to be done to take advantage of the program
Has an advocate available to guide them through the process

The Author, Dr. Gene Emmer, is President of Med Services Europe B.V., a European-based consultancy focused on Sales, Marketing and Business Development of Pharmaceutical and Medical Products. www.MedServicesEurope.com +31648566707

# # #

Still moving in the right direction!!

Yes, we were right, the price is up a couple of pence this week, in spite of it being a SELL recommendation by Investors Chronicle last friday. Trades this week show small ivestors getting out on that rec but some nice chunky buy orders from people who obviously have faith.

Realistic, I have a feeling things are looking up.
The presentations to the city will wake them up.
Another thing to look at is previous historic run ups to end of year.
I think we could double our money from here - imho.
I would trust IC scribblers as far as I could throw them if they say sell buy.

transco.
Quite a few big sells showing today but the price has only eased down a fraction. perhaps these guys are selling short and the mms know it.They could be squeezed in a week.It's time for more posters on this site.

I am small fry, but I doubled my holding yesterday after thinking about it for a good few weeks - tempted in by all those large buys. Hope it comes good quickly because I now need to sell something else to pay for them.

Dont worry eckoh this baby will fly as we approach new year and the city presentations start. This is one of the few bio's with a product to sell with the added bonus of products a plenty in the pipeline.
Realistic - small sellers glad to get rid of em if they read the ic.

Just a couple of buys today with loads of sellers but the price hasn't moved downwards.The mms must be filling their boots. They must know more than I do in order to take on stock and not move the price down a bit.Could it be that they know that big buy orders will be coming soon?

I gave up a long time ago trying to work out the logic of the stock market re price rises and falls - I'm not complaining but how has the price held up today in the face of such large sells?

Transco - Where did you get your info from - spot on anyway.
The appointment on Friday was as expected but the real fireworks will start when the bid stories come through.
those mm are not daft!!

Bad news today,all sellers today,there must be a sell tip out there somewhere.The hiden good news is that the price is only slightly down so the mms must believe that the price will be over 60p soon.

No worries, all small sellers sitting on a profit and nervous about the reaction to the us election - nothing goes up without a few sells on the way - its positive IMHO

Just a thought, the govt have today announced that all cattle over 30months will now enter the food chain and not be incinerated as before.The proviso is that they must all be tested for BSE. Who will get the contract for the test--Protherics or Proteome or somebody else? Any news please?

According to Riley Ace of Spies on the iii Board.

"Bio-Rad achieved 100% market ownership of the UKs BSE test market."

http://www.icas.co.uk/case%20histories/biorad-businesst.html

Thanks for the info CCC. I've been reading Bio-Rads website and you are right. They are convinced that they have got the best.However have they got the capacity for all these tests in this country? Next week Protherics have got a presentation to the institutions and if the BSE test is not mentioned then presumably Bio-Rads have got it signed up. Meanwhile PTI sp does'nt move,so on balance it looks as if there are no big deals.

anybody any ideas on the volume today

vol is up 1)RNS re fidelity just increased its stake,2)new manufacturing plant in U.S. Lots of buyers coming on board, maybe there is a tip out there somewhere.

realistic , thanks for that , saw all the volume but could not make out what the h*ll was going on. still unsure cos funds can move a large amount of shares around without it meaning much

Something is going on.PTI should reach 200 this year.It consolidated a stable trading range of 10p last year.Turnover up 21% 2004.Specialising in toxicity treatments,it is a niche player.VORAXAZE is very interesting because of its use in counteracting the negative effects of chemotherapy...launch in 2006,maybe sooner
14 Jan..DIRECTOR BUYS.Dr.Tony Atkinson buys 300000 shares....does'nt seem a lot
BUT...
20 Jan.Fidelity buys 3,196,327.
Charts look good,so BUY boys BUY.....
I will...always nice to know that there's some anti snakebite treatment out there!

This sp looking very weak recently.The only bad news I can find is the recent load of share options granted to the directors.This obviously dliutes existing shareholder value. Apart from that everthing else seems to be going to plan.Unless anyone out there knows different? Any news ethel?

Yes, I was very enthusiastic back in Jan...and still am but there was no response to my message so I forgot about it waiting for the moving averages to look better.The institutions have accepted PTI as a relatively "safe" prospect compared with some of the biotechs.
The Crofab market est.potential is 80mln dollars.BUT,in Oncology thay have Voraxaze with US and EU MARKETING applications PLANNED for Q2 this year.The initial opportunity estimate is upto 200 mln dollars.At the moment Voraxaze is sold to named patients only.PTI also have Prion and BSE and CJD diagnostics.In the pipeline-Angiotensin Vaccine for Hypertension and NQO2 for liver cancer in clinical development.Cytofab for severe sepsis is going into phase 111 trials.Maybe we will have news about discussions with licensing partners for the latter.Framlington et al are invested in them.Have'nt checked the price yet,but if the averages look good then I shall go in.This share is normally quite predictable and not volatile when it starts to go up.But you see it's not just about snake bite antidotes...this is a great crowd with good products for sale...not just dreams.

Thanks for that ethel. I think I'll stick with them for another year.I bought some at the early rights for 16p so I'm well in front but lately things have been so quiet.We must be thankful that the institutions are prepared to be patient.

Hello again,Realistic...still there?
PTI been tipped for last two weeks.rns today....still no sp move.
Moving averages show hint of a change and am tempted back in,but still wary of the way this company has been ignored by investors.
With the small caps the way they are at the moment,it is difficult to feel confident about particular stocks,even when the fundamentals seem O.K.The sp could be shorted down in the absence of news.As it is ,the one year chart shows that the sp is where it was last autumn,when there was a dir.buy at 50p followed by a nice rise ...the 38 day moving averages even look the same as they did then!
Well,I think I'll go for it,wish us luck and all those others out there,whoever you are.
Ethel

On the move again shortly - moving north big time.

How/what do you know?

Now that would be telling.

Come on,let us share your secret,Transco!
Whatever,the sp is finally moving north.

Just read my earlier posts last year and read between the lines.
This is a top class business, building a long term sound future.

Its time for protherics to fly !!!!!!!!!!!

well still it goes up and up... takeover talk about and discounted rights issue

up on a bad day - plus good volume.

Has nobody noticed this move!!
Come on chaps credit where its due.
What a mover!!! and more to come...

Transco - are you still in? I've taken the plunge today. Downside seems limited whilst upside potential is superb. Fingers crossed.

Protherics PLC
12 January 2006


CYTOFABTM LICENSING AGREEMENT BETWEEN PROTHERICS AND ASTRAZENECA BECOMES
EFFECTIVE FOLLOWING HART-SCOTT-RODINO CLEARANCE


London, UK, Nashville, TN, 12 January 2006 - Following the announcement on 8
December 2005, of the licensing agreement between Protherics and AstraZeneca for
the global development and commercialisation of Protherics' anti-sepsis product
CytoFabTM, it is further announced that the agreement has become effective
following the expiry of the Hart-Scott-Rodino waiting period in the US.

This triggers an immediate initial payment to Protherics of 16.3 million and a
7.5 million equity investment by AstraZeneca in Protherics. The agreement has
further potential milestone payments worth up to 171 million and Protherics
will also receive a 20 percent net royalty on the net global sales of CytoFabTM.

Protherics PLC
20 January 2006


PROTHERICS PLC

NOTIFICATION OF MAJOR INTERESTS IN SHARES

20 January 2005: Protherics PLC (the 'Company'), the biopharmaceutical company
focused on critical care and oncology, received notification today from
Perpetual Income & Growth Investment Trust plc on behalf of INVESCO Asset
Management Limited that Perpetual Income & Growth Investment Trust plc is the
beneficial owner of 10,115,137 ordinary shares representing 3.92% of the issued
share capital of the Company.

This notification follows an increase in the Company's issued share capital to
258,328,129 ordinary shares.

Protherics PLC
20 January 2006



PROTHERICS PLC

NOTIFICATION OF MAJOR INTERESTS IN SHARES


20 January 2006: Protherics PLC, the biopharmaceutical company focused on
critical care and oncology (the 'Company'), received notification on 19 January
2006 from Aviva plc that, as at 18 January 2006, Aviva plc and its subsidiaries
held a beneficial interest in 12,383,731 ordinary shares, representing 4.79% of
the issued share capital of the Company, and a total interest in 27,603,457
ordinary shares, representing 10.68% of the issued share capital of the Company.

This notification follows an increase in the Company's issued share capital to
258,328,129 ordinary shares.

Protherics PLC
20 January 2006



PROTHERICS PLC


NOTIFICATION OF MAJOR INTERESTS IN SHARES


20 January 2005: Protherics PLC (the 'Company'), the biopharmaceutical company
focused on critical care and oncology, received notification on 19 January 2006
from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group
Company ('AXA S.A.') that, on 18 January 2006, AXA S.A. held an interest in
32,099,803 ordinary 2p shares (the 'Shares') in the share capital of the Company
(12.43%).



The Shares are represented by a beneficial interest in 10,000 ordinary shares
(0.004%) and a non-beneficial interest in 32,089,803 ordinary shares (12.422%).



This notification follows an increase in the Company's issued share capital to
258,328,129 ordinary shares.

Lots of splendid news hlyeo98. I especially like the "The agreement has
further potential milestone payments worth up to 171 million and Protherics
will also receive a 20 percent net royalty on the net global sales of CytoFabTM", piece!

There is also a positive article on PTI in the Shares Magazine this week

Indeed - good day today as well. Break 1 tomorrow me thinks.

q1,

Well at present your pediction is wrong. This is not a dig, as I also thought it would break the 1 line. All the indications were looking like a plus 1 today but I suppose there is most of the trading day left. It just shows how volatile share dealing can be. Still I now expect a few small adjustments till we get some news.

There was huge selling yesterday of 2 blocks of more than 1,000,000 each.

greekman - no dig assumed but it did break 1 today, it just didn't stay there...

L2 looking good. 2 on the bid, against 8 on the ask. If the next 3 Set's on the bid go, I would expect it to end up a bit better that the present price of 2.5p down.

I give in trying to read this share.

Hey, what's going on? PTI dropped 5p to 88p today.

When are they going to announce RNS? It is dropping again today to 85.5p now

Back up we go...

A snippet from Sharecast.


AstraZeneca's ditching of Exanta demonstrates the markets faith in the ability of AZ to tackle its meagre pipeline of new products by buying in the necessary new science. With $6 billion of free cash, it should have the financial clout to seal the best deals going says the Times.

My view..... You never know, with their cash, acquisitions may be a way to go. Or they may look toward such companies as Protherics for further licensing agreements. Every little helps.

Nice little article about Crofab.

Fougera Marks Sixth Snakebite Season with CroFab Crotalidae Polyvalent Immune Fab (Ovine)


http://www.primezone.com/newsroom/news.html?d=95910

keep your nerve chaps........lots of upside to come....